Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.
Clinical Pipeline
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/BBB-Logo-TM.png)
LentiGlobin
Indication: Sickle Cell Disease
Phase II / III
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/logo_veana.jpg)
Oral Vimo-001
Indication: Solid Tumors
Phase I
Pre-Clinical Pipeline
![](https://www.claytonbiotech.com/wp-content/uploads/2023/04/Vacunax-logo.jpg)
Dengue Virus Vaccine
Indication: 4 serotype dengue vaccine
IND in preparation
Chikungunya Virus Vaccine
Indication: vaccine to chikungunya
IND enabling studies
Zika Virus Vaccine
Indication: vaccine to zika
IND enabling studies
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/logo_renova.jpg)
RT-200
Indication: Type II Diabetes
Advanced Preclinical
RT-300
Indication: Congestive Heart Failure
Preclinical
RT-400
Indication: Acute decompensated heart failure
Preclinical
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/logo_h2biologics.jpg)
GrB-Fc-SD1
Indication: Mesotheliomas & Pancreatic Cancers
Preclinical
Early Stage Pipeline
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/logo_abologix.jpg)
JamC mAb
Indication: B Cell Lymphomas
Animal in vivo POC
Olfml3 mAb
Indication: Metastatic breast cancer
Animal in vivo POC
SrpX2 mAb
Indication: TBD
Animal in vivo POC
![](https://www.claytonbiotech.com/wp-content/uploads/2019/09/demo-img.png)
GrB platform
Platform technology potent elimination of unwanted cells
Animal POC
Laser IntraVascular lithotripsy
Applications: Chronic Total Occlusions (CTOs) and Brain tumors
Prototype development (Download PDF)
HI P. Goldsteinii
Indication: Osteoporosis and Obesity
Preclinical